Lycera is a biopharmaceutical company focused on developing next-generation drugs to address autoimmune diseases and cancer by modulating the immune system. The company operates in the healthcare and pharmaceutical markets, primarily serving patients suffering from immune system dysregulation. Lycera's business model revolves around advancing clinical and preclinical programs, particularly through the development of RORgamma agonists, which enhance CAR T cell anti-tumor activity and persistence. Revenue is generated through the development and potential commercialization of these innovative therapeutics. The company's integrated research teams, comprising medicinal chemists, immunologists, and physicians, are dedicated to transforming proprietary research findings into novel compounds with significant therapeutic potential.

Keywords: biopharmaceutical, immune modulation, autoimmune diseases, cancer, RORgamma agonists, CAR T cells, clinical programs, preclinical programs, innovative therapeutics, immune system.